Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI
| Title: | Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI |
|---|---|
| Authors: | Erlinge D; James S; Deanfield J; Eriksson N; de Belder M; Alchay M; Austin D; Jones DA; Ravn-Fischer A; Sederholm Lawesson S; Shah N; Strange JW; Szummer K; Ridderstrale W; Parvaresh Rizi E; Langkilde AM; Johansson PA; McGuire DK; Oldgren J; Storey RF |
| Source: | ESC Heart Failure, 2025 |
| Publisher Information: | John Wiley and Sons Inc. |
| Publication Year: | 2025 |
| Collection: | Newcastle University Library ePrints Service |
| Description: | © 2025 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. Aims: In the randomized DAPA-MI clinical trial, 10 mg of dapagliflozin once daily improved cardiometabolic outcomes versus placebo after acute myocardial infarction (MI) in patients without established diabetes or heart failure (HF). We assessed associations between baseline left ventricular ejection fraction (LVEF) and cardiometabolic outcomes in DAPA-MI. Methods: The primary outcome, assessed using the win ratio method, was the hierarchical composite of death, hospitalization for HF, non-fatal MI, atrial fibrillation/flutter, Type 2 diabetes, New York Heart Association classification at last visit and body weight decrease of ≥5% from baseline to last visit. For the present analysis, patients were categorized using LVEF at randomization ( |
| Document Type: | article in journal/newspaper |
| File Description: | application/pdf |
| Language: | unknown |
| Relation: | https://eprints.ncl.ac.uk/307918; https://eprints.ncl.ac.uk/fulltext.aspx?url=307918/853D6BB1-508A-443E-8256-49E3C74824C6.pdf&pub_id=307918 |
| Availability: | https://eprints.ncl.ac.uk/307918 |
| Rights: | https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: | edsbas.17E08785 |
| Database: | BASE |